PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
Transition from An Asset-Heavy Business Model to An Asset-Light Business Model Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible Net Revenue of Promotional Products ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals   Multimedia/Online/Internet 
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG , Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Tianjin University Leads World's 1st ISO Standard for Single-Herb TCM Formula Granules
TIANJIN, China , Sept. 16, 2026 /PRNewswire/ -- The International Organization for Standardization (ISO) has published ISO 21756:2026, the world's first international standard for single-herb Traditional ...
2026-09-17T    Education   Health Care/Hospital   Higher Education   Medical/Pharmaceuticals 
American Savings Bank Raises $129 Million in IPO: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. ...
2026-09-16T    Banking/Financial Service   Computer/Electronics   Health Care/Hospital 
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States ( NCT06635785 ) and in China ( CTR20253261 ) Fast Track Designation Supports Expedited Development of Cesalatamig ...
2026-09-16T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
LANDMARK GLOBAL STUDY REVEALS CRITICAL INEQUITIES IN ACCESS TO DERMATOLOGICAL CARE
First comprehensive global assessment by the International League of Dermatological Societies (ILDS) and L'Oréal Dermatological Beauty spans 158 countries and 97% of the world's population. ...
2026-09-16T    Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics   Infectious Disease Control 
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
SHANGHAI , Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, ...
2026-09-16T    Biotechnology   Environmental Products & Services   Green Technology   Health Care/Hospital 
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks
Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks ...
2026-09-16T    Health Care/Hospital   Medical/Pharmaceuticals 
GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases
The interactive educational website makes NTDs understandable to a general audience, the first step toward public support that drives R&D for the 1.5 billion people affected by these disease ...
2026-09-16T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.